17.50
-0.85%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Yung Zip Chemical Ind Co
Its shares trade on Taipei Exchange under the ticker 4102.TWO. It has been listed since 20 March 2001. In the fiscal year to 31 December 2025, it reported revenue of TWD 474.2m and a net loss of TWD 14.4m. At that date it held total assets of TWD 924.1m and shareholders' equity of TWD 588.3m.
Yung Zip Chemical Ind.Co., Ltd. engages in the manufacturing, importing and exporting active pharmaceutical ingredient. The company is headquartered in Taichung, Taichung. The company went IPO on 2001-03-20. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The firm mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Mar 2001
- Employees
- 193
- Website
- yungzip.com ↗
Leadership
Pay as last reported
- Mr. Ching Hwang LinChairman of the Board, General Manager, Corporate Governance Officer
- Ms. Shuqin XieHead of Finance
- Yufang WangHead of Accounting, since 2020
- Mr. Hongwen JiangDirector
- Mr. Fang Chen LeeDirector, since 1993
- Dato' Dr. Fang-Hsin LeeDirector
- Mr. Fang-Yu LeeDirector, since 2022
- Mr. Yuru LiDirector
- Mr. Yangzong CaiIndependent Director
- Mr. Zisheng WuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 193 full-time employees.
- Products include diclofenac sodium for rheumatoid arthritis treatment.
- Operates in both domestic and international markets including USA, Thailand, Indonesia, and Philippines.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- No details on financial performance or market share provided.
- No information on R&D capabilities or product innovation.
Opportunities
- Expansion into new markets beyond current domestic and international presence.
- Potential growth in pharmaceutical ingredient demand globally.
- Opportunity to leverage existing product portfolio for new applications.
Threats
- No specific threats mentioned in the provided information.
- Dependence on a limited number of products for revenue.
- Competition in the pharmaceutical ingredient market is not detailed.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.